Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Presence of val30Met and val122ile mutations in a patient with hereditary amyloidosis

Abstract

Amyloidosis, caused by a mutation in the transthyretin (TTR) gene, is the most common hereditary type disease. More than 120 mutations have been described, with extensive phenotypic heterogeneity. Val30Met (p.Val50Met) is the most frequent mutation, and patients exhibit polyneuropathy, possibly including cardiac, renal, gastrointestinal, and/or ocular involvement. Val122Ile (p.Val142Ile) is the mutation associated with cardiomyopathy, and few cases have been reported in Brazil. Most individuals are heterozygous for one pathogenic mutation. Herein, we report a compound heterozygote with two pathogenic mutations (Val30Met/ Val122Ile), and a family history of a deceased brother with amyloidosis, who also carried the same TTR gene mutations. The patient presented with neuropathic, cardiac, and renal impairment and a faster disease progression. Cases of the double mutation have been linked to changes in disease presentation. The concomitance of two pathogenic mutations may have contributed to more exuberant manifestations and faster disease progression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411–23.

    Article  CAS  Google Scholar 

  2. Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10:1086–97.

    Article  CAS  Google Scholar 

  3. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86:1036–43.

    Article  Google Scholar 

  4. Pinto MV, Barreira AA, Bulle AS, Freitas MRG, França MC Jr, Gondim FAA, et al. Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy. Arq Neuropsiquiatr. 2018;76:609–21.

    Article  Google Scholar 

  5. Koike H, Tanaka F, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry. 2012;83:152–8. https://doi.org/10.1136/jnnp-2011-301299.

    Article  PubMed  Google Scholar 

  6. Castaño A, Drachman B, Judge D, Maurer M. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2014;20:163–78.

    Article  Google Scholar 

  7. Lavigne-Moreira C, Marques V, Gonçalves M, de Oliveira M, Tomaselli P, Nunez J, et al. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population. J Peripher Nerv Syst. 2018;23:134–7.

    Article  CAS  Google Scholar 

  8. Cruz M, Pinto M, Pinto L, Gervais R, Dias M, Perez C, et al. Baseline disease characteristics in Brazilian patients enrolled in Transthyretin Amyloidosis Outcome Survey (THAOS). Arq Neuropsiquiatr. 2019;77:96–100.

    Article  Google Scholar 

  9. Matsumoto S, Ueda M, Yamashita T, Amano T, Misumi Y, Tasaki M, Masuda T, Mizukami M, Furuya H, Ando Y. A late-onset case of hereditary transthyretin amyloidosis with a novel compound heterozygous mutation. Amyloid. 2017;24:97–8.

    Article  Google Scholar 

  10. Almeida M, Alves I, Terazaki H, Ando Y, Saraiva M. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun. 2000;270:1024–8.

    Article  CAS  Google Scholar 

  11. Terazaki H, Ando Y, Misumi S, Nakamura M, Ando E, Matsunaga N, et al. A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochem Biophys Res Commun. 1999;264:365–70.

    Article  CAS  Google Scholar 

  12. Adams D, Suhr O, Hund E, Obici L, Tournev I, Campistol J, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29:S14–26.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jemima A. da Silva-Batista.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

da Silva-Batista, J.A., Marques Jr, W., Oliveira, M.T.d.J.S. et al. Presence of val30Met and val122ile mutations in a patient with hereditary amyloidosis. J Hum Genet 65, 711–713 (2020). https://doi.org/10.1038/s10038-020-0749-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s10038-020-0749-3

This article is cited by

Search

Quick links